openPR Logo
Press release

Hemophilia Gene Therapy Market 2019 | Future Growth By Top Players BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC Sangamo Therapeutics, Inc., Freeline Therapeutics

06-08-2019 06:25 AM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Hemophilia Gene Therapy

Hemophilia Gene Therapy

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins called clotting factors. There are around 13 types of clotting factors that work with blood platelets, which are necessary for clotting process to initiate. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in clotting factor VIII. Hemophilia B occurs due to deficiency of clotting factor IX and Hemophilia C is caused due to clotting factor XI deficiency. Hemophilia is incurable with current therapeutic options, which only reduces symptoms such as spontaneous bleeding in muscles and joints as well as increased risk for intracranial hemorrhage. These treatment options lasts only for a day and is costly. As against conventional clotting factor replacement therapy, gene therapy is expected to offer sustainable cure for hemophilia by correcting defective gene sequence (F8 or F9 gene) that codes for clotting factor VIII or IX in the patient’s body.

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2480

The global hemophilia gene therapy market was valued at US$ 0.00 million in 2017 and is expected to witness a CAGR of 56.0% over the forecast period (2018 – 2026).

High prevalence of hemophilia is increasing demand for sustainable treatment of the disease, which is projected to drive the market growth over the forecast period. According to the National Hemophilia Foundation factsheet 2018, hemophilia affected over 400,000 individuals worldwide. Moreover, according to same source, an estimated 75% of patients suffering from hemophilia have no access to treatment or receive inadequate treatment. According to the Centers for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is around four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.

Gene therapy for hemophilia has strong product pipeline, which is expected to enter the market in the near future. This is expected to drive the market growth, as it would result in availability of new treatment options for management of hemophilia. By Januarys 2019, over 15 investigational gene therapy are under the clinical development stage. In December 2018, Spark Therapeutics announced updated preliminary data for the ongoing phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A.

Current therapies for treating hemophilia are only symptomatic management of the disease by administering clotting factors XIII or IX. Furthermore, there are serious adverse effects associated with plasma derived products, and limited access to treatment. Gene therapy may address these issues to certain level. BioMarin Pharmaceutical’s gene therapy product Valoctocogene roxaparvovec for hemophilia A is in phase III of clinical development in 2019.

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2480

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) are supporting the product development for gene therapy by allotting breakthrough designation status to investigational gene therapy. For instance, in 2017, the U.S. FDA granted breakthrough therapy designation to valoctocogene roxaparvovec, which is an Adeno -associated virus 5 factor VIII vector designed to restore factor VIII plasma concentrations in patients with hemophilia A.

Key players operating in the global hemophilia gene therapy market include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC Sangamo Therapeutics, Inc., and Freeline Therapeutics.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemophilia Gene Therapy Market 2019 | Future Growth By Top Players BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC Sangamo Therapeutics, Inc., Freeline Therapeutics here

News-ID: 1768635 • Views:

More Releases from Coherent Market Insights (CMI)

Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2030 | Carestream Health, Accurate Imaging, Inc., Alliance HealthCare Services
Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2 …
𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄: Mobile imaging services are provided by trained professionals who are equipped with state-of-the-art imaging technology that can be transported and set up on location. The images obtained through mobile imaging services are then transmitted electronically to the patient's healthcare provider for analysis and diagnosis. Mobile imaging services are used in a variety of healthcare settings, including hospitals, clinics, nursing homes, and home health agencies. They are particularly useful for imaging patients
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | Ion Beam Applications, Provision Healthcare, Mevion Medical Systems
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | I …
Coherent Market Insight has published a new research report titled "Particle Therapy Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Toshiba Corporation, Carestream Health, General Electric Company
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Tosh …
Coherent Market Insight has published a new research report titled "Digital Mobile X Ray Devices Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns,
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities 2030 | LI-COR Biosciences, Analytik Jena US, Azure Biosystems, Berthold Technologies GmbH & Co. KG
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities …
Coherent Market Insight has published a new research report titled "Chemiluminescence Imaging Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and

All 5 Releases


More Releases for Hemophilia

Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes
Hemophilia Treatment Drugs Market Report 2024
Global Hemophilia Treatment Drugs Market: Overview The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia